8-K: Enhabit Reports Mixed Q2 Results, Non-Medicare Growth Offsets Medicare Decline

Enhabit's second quarter results show a mixed performance with strong non-Medicare admissions growth offsetting a decline in Medicare revenue, while the company updates its full-year guidance.

Summary

• Enhabit reported its second quarter 2024 financial results, showing a net service revenue of $260.6 million and a net loss of $0.2 million.
• Adjusted EBITDA for the quarter was $25.2 million, and adjusted earnings per share were $0.07.
• The company experienced a 6.4% year-over-year increase in total admissions, driven by a 25.2% growth in non-Medicare admissions.
• However, Medicare admissions decreased by 10.5%, and Medicare revenue declined by 12.7%.
• Hospice average daily census increased by 2.7% year-over-year and sequentially every month since January 2024.
• Enhabit reduced its bank debt by $15 million during the quarter.
• The company updated its full-year 2024 guidance, lowering the net service revenue range to $1,050 to $1,063 million and adjusting the adjusted EPS range to $0.19 to $0.37.

Sentiment

Score: 5

Explanation: The sentiment is neutral to slightly negative. While there are positive aspects like non-Medicare growth and improved clinical outcomes, the lowered guidance and net loss temper the overall outlook. The company is showing progress in some areas but faces challenges in others.

Positives

• Non-Medicare admissions showed strong growth, increasing by 25.2% year-over-year.
• The company's payor innovation strategy is proving successful, with 43% of non-Medicare visits under improved contracts.
• Home health readmission rates are significantly better than the national average, indicating high-quality care.
• Hospice census has shown consistent growth, with increases every month since January 2024.
• Enhabit has successfully reduced its bank debt by $15 million in the quarter.
• Adjusted EBITDA increased by 5.4% year-over-year, demonstrating improved profitability.

Negatives

• Medicare admissions decreased by 10.5% year-over-year.
• Home health net service revenue declined by 1.7% year-over-year, primarily due to lower Medicare volume.
• The company reported a net loss of $0.2 million for the quarter.
• The company has lowered its full-year revenue guidance from $1,076-$1,102 million to $1,050-$1,063 million.
• The company has lowered its full-year adjusted EPS guidance from $0.12-$0.43 to $0.19-$0.37.

Risks

• The company faces risks related to regulatory changes and reimbursement rates.
• There are potential disruptions to information systems and the outcome of litigation.
• The company's ability to control costs, particularly labor and employee benefits, is a risk.
• The company's ability to successfully integrate new locations and acquisitions is a risk.
• The company's ability to execute on its strategic plans is a risk.

Future Outlook

The company updated its full-year 2024 guidance, lowering the net service revenue range to $1,050 to $1,063 million and adjusting the adjusted EPS range to $0.19 to $0.37. The company expects to continue growing admissions at midto high-single digits over the next three years.

Management Comments

• Enhabit's President and Chief Executive Officer, Barb Jacobsmeyer, stated that the second quarter marked the third sequential quarter demonstrating the success of their strategies.
• She also noted that the company's focus on recruitment and retention continues to position them for long-term growth.

Industry Context

The results reflect the ongoing shift in healthcare towards home-based care, with Enhabit focusing on payor innovation and non-Medicare growth to offset challenges in the traditional Medicare market. The company's focus on improving clinical outcomes and reducing hospital readmissions aligns with industry trends towards value-based care.

Comparison to Industry Standards

• Enhabit's 30-day hospital readmission rate in home health is 23.3% better than the national average, indicating a strong performance compared to industry benchmarks.
• The company's hospice patient visits in the last days of life are 53.2% better than the national average, demonstrating a commitment to high-quality end-of-life care.
• While specific competitor data is not provided, Enhabit's focus on non-Medicare growth and payor innovation suggests a strategic response to industry-wide pressures on Medicare reimbursement.
• The company's adjusted EBITDA margin of 9.7% is a key metric to compare against peers in the home health and hospice industry, though specific competitor data is not provided in the document.

Stakeholder Impact

• Shareholders may be concerned about the lowered guidance and net loss.
• Employees may be impacted by the company's focus on cost control.
• Patients and their families should benefit from the company's focus on high-quality care and improved outcomes.
• Payors may be interested in the company's payor innovation strategy and its ability to manage costs.

Next Steps

• The company will host an investor conference call on August 7, 2024, to discuss the second quarter results.
• Enhabit will continue to focus on its payor innovation strategy and growing its non-Medicare business.
• The company will continue to focus on recruitment and retention of clinical staff.
• The company will continue to open de novo locations.

Key Dates

Keywords

home health, hospice, admissions, Medicare, non-Medicare, EBITDA, revenue, census, payor innovation, readmission rate